Braveheart Bio
BRVE
18.58
-1.21
-6.11%
Braveheart Bio
US · BRVE
#2845 by market cap
Listed 2026
18.58
-1.21
-6.11%
Live - 5344 symbols - heartbeat 374s ago
· 2026-10-08 07:00
Pre-market
18.58
0.00%
After-hours
18.58
0.00%
- Market cap
- 1.67B
- P/E (TTM)i
- -3.01
- P/Bi
- -17.45
- EPSi
- -0.94
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on BRVE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 7 in the most recent period (2026/Q3).
- Total institutional ownership rose 65.9 percentage points.
Institutional ownership
- Held by institutions
- 68.93% +65.91pp
- Institutions
- 8 +7
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund59.85%
Individual/Insider15.11%
Public Company9.00%
Other15.96%
Top holders as of 2026-08-07
Forbion Capital Partners B.V.
26.47% · 21.83M sh
OrbiMed Advisors LLC
14.77% · 12.18M sh
Andreessen Horowitz LLC
12.41% · 10.23M sh
Travis Murdoch
10.11% · 8.33M sh
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
9.00% · 7.42M sh
Frazier Life Sciences Management, LP
6.19% · 5.11M sh
Jason Coloma
1.71% · 1.10M sh
David Malek
1.23% · 1.01M sh
James Rickey
0.85% · 703.58K sh
Christopher Viehbacher
0.74% · 609.52K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
34 filings tracked · 22 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Forbion Capital Partners B.V. | -- | 26.47% |
| OrbiMed Advisors LLC | -- | 14.77% |
| Andreessen Horowitz LLC | -- | 12.41% |
| Travis Murdoch | Chief Executive Officer | 10.11% |
| Jason Coloma | Director | 1.71% |
| David Malek | Director | 1.23% |
| James Rickey | Chief Financial Officer | 0.85% |
| Christopher Viehbacher | Independent Chairperson | 0.74% |
| Michele Anderson | Chief Development Officer | 0.40% |
| David Lubner | Independent Director | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-06 | OrbiMed Advisors LLC | -- | Private Acquisition | +1,940,000 | $18.00 |
| 2026-08-06 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +9,132,420 | -- |
| 2026-08-06 | David Lubner | Independent Director | Private Acquisition | +55,555 | $18.00 |
| 2026-08-06 | Christopher Viehbacher | Independent Chairperson | Private Acquisition | +83,333 | $18.00 |
| 2026-08-06 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Derivative Exercise and Retained | +7,420,091 | -- |
| 2026-08-06 | Forbion Capital Partners B.V. | -- | Private Acquisition | +3,600,000 | $18.00 |
| 2026-08-06 | Forbion Capital Partners B.V. | -- | Derivative Exercise and Retained | +17,123,287 | -- |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Private Acquisition | +1,100,000 | $18.00 |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Derivative Exercise and Retained | +9,132,420 | -- |
| 2026-08-06 | Andreessen Horowitz LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-06 | David Malek | Director | Private Acquisition | +4,166 | $18.00 |
| 2026-08-06 | James Rickey | Chief Financial Officer | Private Acquisition | +27,777 | $18.00 |
| 2026-08-06 | Michele Anderson | Chief Development Officer | Private Acquisition | +1,111 | $18.00 |
| 2026-08-06 | Travis Murdoch | Chief Executive Officer | Private Acquisition | +83,333 | $18.00 |
| 2026-08-04 | OrbiMed Advisors LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | David Lubner | Independent Director | Other Derivative Acquisition | +60,000 | $18.00 |
| 2026-08-04 | Christopher Viehbacher | Independent Chairperson | Other Derivative Acquisition | +30,000 | $18.00 |
| 2026-08-04 | Christopher Viehbacher | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | Erez Chimovits | Independent Director | Other Derivative Acquisition | +30,000 | $18.00 |
| 2026-08-04 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:27 · For reference only, not investment advice and not tailored to your situation.